NEFL and Alzheimer disease: In addition, plasma biomarkers such as the ratio of amyloid beta (Aβ42/Aβ40), neurofilament light (NEFL/NfL), and glial fibrillary acidic protein (GFAP) hold significant potential for AD diagnosis and monitoring [9, 10].